Your browser doesn't support javascript.
loading
Novel recombinant human thyroid-stimulating hormone in aiding postoperative assessment of patients with differentiated thyroid cancer-phase I/II study.
Lin, Yan-Song; Yang, Hui; Li, Xiao-Yi; Wu, Li-Qing; Xu, Jin-Guo; Yang, Ai-Min; Gao, Zai-Rong; Ding, Yong; Zhang, Ying-Qiang; Chen, Kai; Mu, Zhuan-Zhuan; Jia, Jian-Min; Niu, Na; Sun, Di; Zhang, Xin; Zhang, Shao-Qiang; Geng, Qian-Qian; Zhang, Ya-Jing; Chen, Fang-Ni; He, Bao-Xia.
Affiliation
  • Lin YS; Department of Nuclear Medicine, Dongcheng District, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, No.1 Shuaifuyuan, Wangfujing St, Beijing, 100730, China. linyansong1968@163.com.
  • Yang H; State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China. linyansong1968@163.com.
  • Li XY; Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China. linyansong1968@163.com.
  • Wu LQ; Department of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Xu JG; Department of General Surgery, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, Beijing, China.
  • Yang AM; Clinical Research Department, Suzhou Zelgen Biopharmaceuticals Co., Ltd, Suzhou, China.
  • Gao ZR; Biological R&D Department, Suzhou Zelgen Biopharmaceuticals Co., Ltd, Suzhou, China.
  • Ding Y; Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China.
  • Zhang YQ; Department of Nuclear Medicine, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
  • Chen K; Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China.
  • Mu ZZ; Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, China.
  • Jia JM; Department of Nuclear Medicine, The Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.
  • Niu N; Department of Nuclear Medicine, Dongcheng District, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, No.1 Shuaifuyuan, Wangfujing St, Beijing, 100730, China.
  • Sun D; State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China.
  • Zhang X; Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China.
  • Zhang SQ; Department of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Geng QQ; Department of Nuclear Medicine, Dongcheng District, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, No.1 Shuaifuyuan, Wangfujing St, Beijing, 100730, China.
  • Zhang YJ; State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China.
  • Chen FN; Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China.
  • He BX; Department of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Eur J Nucl Med Mol Imaging ; 49(12): 4171-4181, 2022 Oct.
Article in En | MEDLINE | ID: mdl-35781600
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thyroid Neoplasms / Adenocarcinoma / Thyrotropin Alfa Limits: Humans Language: En Journal: Eur J Nucl Med Mol Imaging Journal subject: MEDICINA NUCLEAR Year: 2022 Type: Article Affiliation country: China
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thyroid Neoplasms / Adenocarcinoma / Thyrotropin Alfa Limits: Humans Language: En Journal: Eur J Nucl Med Mol Imaging Journal subject: MEDICINA NUCLEAR Year: 2022 Type: Article Affiliation country: China